Attached (PDF file here) are the KEI comments on the proposed NIH exclusive license to miRecule for MicroRNA Therapeutics for Treating Squamous Cell Carcinomas.
The seven page letter concludes with these words:
Continue Reading →
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Susan Ano, Ph.D., NINDS Technology Transfer, 31 Center Drive, Suite 8A52, MSC2540 Bethesda, MD 20892; Telephone: (301) 435-5515; anos@mail.nih.gov Dear Dr. Ano, I am writing to express… Continue Reading →
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702… Continue Reading →
KEI has obtained the terms of reference (TOR) for the confidentiality of the negotiating texts of the Transatlantic Trade and Investment Partnership (TTIP) Agreement. The TOR are laid out in a two-page letter from US Chief Negotiator Dan Mullaney to EU Chief Negotiator Ignacio Garcia-Bercero which is available here. The letter was obtained through a FOIA request filed by KEI with the USTR on May 19, 2014.
Continue Reading →
Comments of KEI, regarding USTR Request For Comments From The Public On The Creation Of The Public Interest Trade Advisory Committee And Request For Nominees To That Committee.
Submitted to Regulations.gov on March 25, 2014, under docket number USTR-2014-0005.
Intellectual property issues are an important element of US trade agreements, and according to a recent study by Open Secrets, the most intensively lobbied issue, by far.
Continue Reading →
On August 30, 2013 KEI filed the following FOIA request for copies of any email correspondence between Victoria Espinel, the former US Intellectual Property Enforcement Coordinator, and employees, representatives, or member companies of the Business Software Alliance (BSA). Espinel assumed the position of President and CEO of BSA just weeks after stepping down from her position at OMB. KEI is interested in the ethical dimensions of Espinel’s new employment, in light of Executive Order 13490 — Ethics Commitments.
——– Forwarded Message ——–
From: Claire Cassedy
Continue Reading →
In June of 2010, KEI was informed that representatives from the the United States Food and Drug Administration (FDA) had recently attended a summit in India on the issue of counterfeited and spurious medicines organized by the Partnership for Safe Medicines (PSM), a US-based organization with clear links to pharmaceutical corporate interests.
Continue Reading →
Background
On October 14, 2009, KEI submitted a FOIA request to the USTR, which is available here, asking for the following records:
KEI requests all records at USTR on the topic of the policy and practice of USTR regard the transparency of trade negotiations, including but not limited to the Anti-Counterfeiting Trade Agreement (ACTA).
Continue Reading →
